The Eindhoven, The Netherlands-based spinal cord stimulation technology developer plans for ten Hoedt to become chair at year-end. This follows the planned retirement of Jan Ohrstrom, current director and chair, after eight years.
ten Hoedt most recently served as EVP and president of global regions at Medtronic. He originally joined Medtronic in 1991 with the title of marketing manager for Western Europe’s neurological business. ten Hoedt retired from his post at the medtech giant earlier this year.
Onward said ten Hoedt joins its board as the company transitions to a commercial enterprise. It plans to launch its ARC-EX spinal cord stimulation in the U.S. later this year. In addition to the ARC-EX, Onward develops the ARC-IM system that could work as part of a brain-computer interface.
CEO Dave Marver said he has a relationship with ten Hoedt dating back two decades when they worked together at Medtronic. He lauded the new board chair’s energy, network, mindset and commitment to mission-driven initiatives.
“I am honored and excited to join the board of this exceptional company,” Ten Hoedt said in a news release. “I have always been drawn to opportunities to make a difference, address unmet needs, and confront unsolved challenges. I look forward to working with Dave Marver and the rest of the board and management team to help Onward achieve its vast potential.”
Onward makes another addition to its board
To align with its shift to commercial activities, Onward also named Rahma Samow to its board. The current president and CEO of ClearChoice Dental Implant Centers brings digital health and direct-to-consumer expertise to the board. Past roles included service on the board at Straumann Group and 15 years at Siemens Healthineers.
“I’m thrilled about the fresh perspective and expertise Rahma brings to the Company,” said Marver. “She will help us build communities among the people we serve, as well as their loved ones, many of whom actively seek information and guidance online. With her extensive experience in global sales and marketing, Rahma will also help us navigate the complexities of commercializing our therapies in international markets, whether directly or through collaboration with distribution partners.”
Both ten Hoedt and Samow will join the board this month and participate in the company’s planned December board meeting. Onward expects its shareholders to formally ratify their appointments at the 2025 annual general meeting.
Marver said that Fred Colen also departs the board alongside Ohrstrom
“I want to thank and recognize Jan for his eight years of outstanding and committed service to our board and company,” said Marver. “I have enjoyed working with Jan immensely and wish him the best as he steps down to spend more time with family and pursue personal interests. He has earned the right to do more sailing.”
“I would also like to thank Fred Colen for his many years of service to our board and company. The company is grateful to both Jan and Fred for their guidance during our journey from a mere start-up to a public company on the verge of commercialization.”
